Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Program Overview

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced non-small cell lung cancer (NSCLC).

Credit Expired

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Faculty


Ahmet Sezer, MD

Professor, Medical Oncology
Başkent University
Adana, Turkey

Head Shot YMS2312_0228_Goldberg (2)

Sarah B. Goldberg, MD, MPH

Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT

Brian Henick

Brian Henick, MD

Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources